You are here: Industry Insights > gilead

News List

Roche Initiates Phase III Trial in COVID-19 Pneumonia contractpharma
May 29, 2020
To evaluate Actemra/RoActemra plus remdesivir in hospitalized patients with severe Pneumonia.
Gilead and Arcus Biosciences partner to develop cancer drugs pharmaceutical-technology
May 29, 2020
Gilead Sciences has partnered with Arcus Biosciences to jointly develop and commercialise current and future cancer therapeutic candidates in the latter’s pipeline.
UK grants early access to Gilead’s remdesivir for Covid-19 pharmaceutical-technology
May 28, 2020
The UK Government has announced that some adults and adolescents hospitalised with Covid-19 on the National Health Service (NHS) will have access to Gilead Sciences’ remdesivir.
Gilead and Galapagos announce positive topline results of phase 2b/3 trial of filgotinib in moderate pharmaceutical-business-review
May 27, 2020
Gilead Sciences and Galapagos announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily ...
Mylan partners with Gilead to manufacture remdesivir, potential COVID-19 treatment europeanpharmaceuticalreview
May 15, 2020
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
Gilead signs Voluntary Licensing Agreements with Cipla, Hetero Labs, Jubilant Lifesciences, Mylan fo expresspharma
May 14, 2020
Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly.
Cipla enters into a licensing agreement With Gilead to expand access to COVID-19 treatment expresspharma
May 13, 2020
As part of the agreement, Cipla will be permitted to manufacture the API and Finished product, and market it in 127 countries including India and South Africa under Cipla’s own brand name.
Jubilant Life Sciences and Gilead sign agreement for Remdesivir expresspharma
May 13, 2020
Jubilant will now have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to COVID-19 patients upon approvals by regulatory authorities in respective countries.
Gilead, Mylan Ink Global Remdesivir License Agreement contractpharma
May 13, 2020
To supply Remdesivir for potential COVID-19 treatment in 127 low- and middle-income countries.
Japanese regulator approves Gilead’s remdesivir to treat Covid-19 pharmaceutical-technology
May 11, 2020
Gilead Sciences has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug remdesivir, under the brand name Veklury, to treat Covid-19 infection.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page